


## Besifloxacin Hydrochloride

<b>Cat. No.:</b>	HY-17028
<b>CAS No.:</b>	405165-61-9
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>22</sub> Cl <sub>2</sub> FN <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	430.3
<b>Target:</b>	Bacterial; Antibiotic
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	Ethanol : < 1 mg/mL (ultrasonic) (insoluble) DMSO : < 1 mg/mL (insoluble or slightly soluble) H <sub>2</sub> O : < 0.1 mg/mL (insoluble)
-----------------	--

### BIOLOGICAL ACTIVITY

<b>Description</b>	Besifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic. IC <sub>50</sub> Value: Target: Antibacterial. Besifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro. Besifloxacin is a novel 8-chloro-fluoroquinolone agent with potent, bactericidal activity against prevalent and drug-resistant pathogens. Besifloxacin is the most potent agent tested against gram-positive pathogens and anaerobes and is generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrates potent, broad-spectrum activity, which is particularly notable against gram-positive and gram-negative isolates that are resistant to other fluoroquinolones and classes of antibacterial agents.
<b>IC<sub>50</sub> &amp; Target</b>	Quinolone

### REFERENCES

- [1]. Wang Z, Wang S, Zhu F, Chen Z, Yu L, Zeng S. Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization. *Chirality*. 2012 Jul;24(7):526-31. doi: 10.1002/chir.22042.
- [2]. Hussar DA. New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine. *J Am Pharm Assoc* (2003). 2009 Jul-Aug;49(4):570-4.
- [3]. Nafziger AN, Bertino JS Jr. Besifloxacin ophthalmic suspension for bacterial conjunctivitis. *Drugs Today (Barc)*. 2009 Aug;45(8):577-88.
- [4]. Proksch JW, Ward KW. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. *J Ocul Pharmacol Ther*. 2010 Oct;26(5):449-58.
- [5]. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. *Paediatr Drugs*. 2010 Apr 1;12(2):105-12. doi: 10.2165/11534380-000000000-00000.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA